Products

Natalizumab (TP-091CL)

Humanized IgG4k monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to a4-integrin. Natalizumab was voluntarily withdrawn from U.S. market because of risk of Progressive multifocal leukoencephalopathy (PML). It was returned to market July, 2006.      

Specifications
Classify
Protein therapeutics that interfere with a molecule or organism: Immunoregulation
Therapeutic
Natalizumab
Function
Mechanism unknown; humanized mAb that binds to the α4-subunit of α4β1 and α4β7 integrins, blocking their interactions with vcAM1 and MadcAM1, respectively
Examples of Clinical Use
Relapsing multiple sclerosis
References
Synonyms
Anti-alpha4 integrin, Anti-VLA4

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-871-5806
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-871-5806    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2017 Creative-Biolabs All Rights Reserved